| 薛 鹏,徐芃芃,毛 昀.非小细胞肺癌免疫检查点抑制剂相关性肺炎研究进展[J].中国肿瘤,2019,28(5):367-372. |
| 非小细胞肺癌免疫检查点抑制剂相关性肺炎研究进展 |
| Research Progress on Checkpoint Inhibitor-related Pneumonitis in Non-small Cell Lung Cancer |
| 投稿时间：2019-02-19 |
| DOI：10.11735/j.issn.1004-0242.2019.05.A009 |
|
 |
| 中文关键词: 非小细胞肺癌 免疫检查点抑制剂 免疫检查点抑制剂相关性肺炎 |
| 英文关键词:non-small cell lung cancer immune checkpoint inhibitors checkpoint inhibitor-related pneumonitis |
| 基金项目: |
|
| 摘要点击次数: 3260 |
| 全文下载次数: 619 |
| 中文摘要: |
| 摘 要：免疫检查点抑制剂主要包括细胞毒性T淋巴细胞抗原4（CTLA-4）抗体和程序性细胞死亡蛋白-1（PD-1）及配体（PD-L1）单克隆抗体，在非小细胞肺癌治疗中表现出良好疗效。免疫检查点抑制剂相关性肺炎（checkpoint inhibitor-related pneumonitis，CIP）临床发生率低，但易造成免疫治疗延迟或终止，严重可导致死亡。接受免疫检查点抑制剂治疗后出现新发呼吸道症状的患者必须高度怀疑肺炎。该综述简要介绍了CIP的流行病学、机制和临床特点等，并讨论CIP的治疗策略。 |
| 英文摘要: |
| Abstract：Immunological checkpoint inhibitors，including anti-CTLA-4，PD-1 and PD-L1 monoclonal antibodies，have shown exciting clinical benefits in treatment of non-small cell lung cancer. Immune checkpoint inhibitor-related pneumonitis (CIP) is of low incidence but might lead to treatment delay or discontinued，even life-threatening to the patient. Pneumonia should be highly suspected in patients newly presenting respiratory symptoms following checkpoint inhibitor therapy. In the review the epidemiology，mechanism，clinical and radiologic manifestation，and the management strategies of CIP are discussed. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |